PCV48 ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67459-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)67459-1/fulltext
Title :
PCV48 ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67459-1&doi=10.1016/S1098-3015(10)67459-1
First page :
Section Title :
Open access? :
No
Section Order :
24